Elanco Animal Health (ELAN) EBITDA Margin (2017 - 2026)
Elanco Animal Health (ELAN) posted EBITDA Margin of 22.39% for Q1 2026, up 62.13% sequentially from 13.81% in Q4 2025, and up 152.0% YoY from 8.89% in Q1 2025.
Elanco Animal Health (ELAN) EBITDA Margin (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of EBITDA Margin data on file, last reported at 22.39% in Q1 2026.
- Quarterly EBITDA Margin rose 152.0% year-over-year to 22.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.43% (up 3467.0% YoY) and the FY2025 annual result came in at 16.86%, up 5099.0% from the prior year.
- EBITDA Margin improved to 22.39% in Q1 2026 per ELAN's latest filing, from 13.81% in the prior quarter.
- The five-year high for EBITDA Margin was 22.39% in Q1 2026, with the low at 148.31% in Q3 2023.
- Average EBITDA Margin over 5 years is 30.39%, with a median of 41.74% recorded in 2024.
- Year-over-year, EBITDA Margin slumped 9802 bps in 2023 and surged 15482 bps in 2024.
- Elanco Animal Health's EBITDA Margin stood at 54.52% in 2022, then decreased by 14 bps to 62.13% in 2023, then rose by 13 bps to 54.12% in 2024, then soared by 126 bps to 13.81% in 2025, then soared by 62 bps to 22.39% in 2026.
- Business Quant data shows ELAN's EBITDA Margin at 22.39% in Q1 2026, 13.81% in Q4 2025, and 14.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.67 Bn | 34.93 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 30.59 Bn | 28.65 Bn | 1.62 Bn | 36.83% |
| 3 | RedHill Biopharma | 26.22 Bn | 26.22 Bn | - | - |
| 4 | United Therapeutics | 23.80 Bn | 21.65 Bn | 648.10 Mn | 41.69% |
| 5 | Curaleaf Holdings | 23.70 Bn | 23.70 Bn | 157.29 Mn | 0.23% |
| 6 | Viatris | 18.69 Bn | 16.89 Bn | 1.16 Bn | -2.27% |
| 7 | Neurocrine Biosciences | 16.86 Bn | 15.54 Bn | 800.70 Mn | 22.74% |
| 8 | Elanco Animal Health | 11.99 Bn | 11.57 Bn | 785.00 Mn | 22.39% |
| 9 | Dr Reddys Laboratories | 11.65 Bn | 11.51 Bn | - | - |
| 10 | Vireo Growth | 10.64 Bn | 10.52 Bn | 59.30 Mn | 9.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.39% |
| Dec 31, 2025 | 13.81% |
| Sep 30, 2025 | 14.69% |
| Jun 30, 2025 | 17.81% |
| Mar 31, 2025 | 20.87% |
| Dec 31, 2024 | -54.12% |
| Sep 30, 2024 | 6.50% |
| Jun 30, 2024 | -44.51% |
| Mar 31, 2024 | -41.74% |
| Dec 31, 2023 | -62.13% |
| Sep 30, 2023 | -148.31% |
| Jun 30, 2023 | -48.53% |
| Mar 31, 2023 | -30.71% |
| Dec 31, 2022 | -54.52% |
| Sep 30, 2022 | -50.29% |
| Jun 30, 2022 | -42.38% |
| Mar 31, 2022 | -35.40% |
| Dec 31, 2021 | -57.10% |
| Sep 30, 2021 | -55.88% |
| Jun 30, 2021 | -61.66% |